docetaxel anhydrous has been researched along with Carcinoma, Transitional Cell in 63 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (11.11) | 18.2507 |
| 2000's | 27 (42.86) | 29.6817 |
| 2010's | 19 (30.16) | 24.3611 |
| 2020's | 10 (15.87) | 2.80 |
| Authors | Studies |
|---|---|
| Ando, R; Banno, R; Etani, T; Hamamoto, S; Iida, K; Isobe, T; Kawai, N; Kubota, H; Nagai, T; Naiki, T; Naiki-Ito, A; Noda, Y; Nozaki, S; Shimizu, N; Sugiyama, Y; Tomiyama, N; Yasui, T | 1 |
| Bamias, A; Bell-McGuinn, KM; Castellano, D; de Wit, R; Drakaki, A; Fléchon, A; Gao, L; Lee, JL; Long, A; Matsubara, N; Necchi, A; Petrylak, DP; Powles, T; Sternberg, CN; van der Heijden, MS; Walgren, RA; Yu, EY; Zimmermann, AH | 1 |
| Clark, PE; Meeks, JJ; Sexton, WJ | 1 |
| Baltezor, M; diZerega, G; Marin, A; Maulhardt, H; Verco, S | 1 |
| Campbell, M; Castellano, D; Duran, I; Lee, JL; Loriot, Y; Mamtani, R; Matsangou, M; Matsubara, N; Petrylak, DP; Powles, T; Rosenberg, JE; Sonpavde, GP; Vulsteke, C; Wu, C | 1 |
| Akapame, S; Banek, S; Burgess, EF; Deprince, K; Guadalupi, V; Houede, N; Huddart, RA; Kean, Y; Ku, JH; Loriot, Y; Matsubara, N; Mukhopadhyay, S; Park, SH; Siefker-Radtke, AO; Stone, NL; Tran, B; Triantos, S; Valderrama, BP | 1 |
| Akita, H; Ando, R; Chaya, R; Etani, T; Iida, K; Kobayashi, D; Moritoki, Y; Nagai, T; Naiki, T; Nozaki, S; Okamura, T; Sugiyama, Y; Yanase, T; Yasui, T | 1 |
| Bajorin, D; Bellmunt, J; Enokida, H; Frenkl, T; Fujimoto, K; Fukasawa, S; Imai, K; Nishimura, K; Nishiyama, H; Perini, R; Sassa, N; Shimamoto, T; Takahashi, K; Tanaka, Y; Yamamoto, Y; Yokoyama, M | 1 |
| Lotan, Y; Meng, X | 1 |
| Atallah, W; Gupta, M; Katims, AB; Mehrazin, R; Rosen, DC; Tam, AW; Zampini, AM | 1 |
| Bell-McGuinn, K; de Wit, R; Drakaki, A; Lee, JL; Liepa, AM; Mao, H; Matsubara, N; Necchi, A; Nishiyama, H; Petrylak, DP; Powles, T | 1 |
| Alekseev, B; Bamias, A; Bell-McGuinn, KM; Castellano, D; Chi, KN; Cicin, I; Coskun, HS; de Wit, R; Del Muro, XG; Drakaki, A; Fléchon, A; Géczi, L; Hamid, O; Harputluoglu, H; Hegemann, M; Hussain, S; Laestadius, F; Lee, JL; Liepa, AM; Matsubara, N; Necchi, A; Nishiyama, H; Ou, YC; Peer, A; Percent, IJ; Petrylak, DP; Powles, T; Rodriguez-Vida, A; Safina, S; Semenov, A; Sternberg, CN; Su, WP; Tortora, G; Tucci, M; van der Heijden, MS; Walgren, RA; Widau, RC; Yu, EY; Zimmermann, AH | 1 |
| J Pelletier, D; Liu, V; O'Donnell, M; Stone, MS | 1 |
| Albany, C; Alter, R; Alva, A; Anderson, K; Balar, A; Bellmunt, J; Breen, T; Choueiri, TK; George, S; Grivas, P; Guancial, EA; Hahn, NM; Hoffman-Censits, J; Hoimes, C; Jacobs, C; Lalani, AA; Lauer, R; Pal, S; Picus, J; Regan, MM; Rosenberg, JE; Sonpavde, G; Stein, MN; Werner, L | 1 |
| Aujla, PK; Beckett, LA; Lara, PN; Li, Y; Pan, CX; Parikh, M; Robles, DA | 1 |
| Chi, KN; Eigl, BJ; Forbes, C; Parimi, S; Tsang, ES | 1 |
| Gschwend, JE; Horn, T; Maisch, P; Retz, M; von Amsberg, G | 1 |
| Carles, J; Maldonado, X; Morales-Barrera, R; Morote, J; Nuñez, I; Suárez, C; Valverde, C | 1 |
| Eberhart, C; Goldberg, MF; Hsu, AW; Montaner, S; Sodhi, A | 1 |
| Hashimoto, Y; Hatakeyama, S; Imai, A; Koie, T; Ohyama, C; Yoneyama, T | 1 |
| Hwang, IG; Kim, YS; Lee, J; Lee, SC; Lee, SI; Lim, HY; Park, S; Park, SH; Sun, JM | 1 |
| Albany, C; Sonpavde, G | 1 |
| Aragon-Ching, JB; Burke, JM; Canil, C; Cavanaugh, CT; Chi, KN; Eisen, A; Gao, L; Kauh, JS; Kim, JJ; Kohli, M; Pan, CX; Petrylak, DP; Quinn, DI; Shaffer, D; Spira, A; Sridhar, SS; Tagawa, ST; Tang, S; Vogelzang, NJ; Walgren, RA; Yu, EY; Zhang, H | 1 |
| Baker, H | 1 |
| Apolo, AB; De Santis, M; Galsky, MD; Leibovich, BC; Milowsky, MI; Pham, MN; Pisters, LL; Siefker-Radtke, AO; Sonpavde, G; Steinberg, GD; Sternberg, CN; Tagawa, ST; Weizer, AZ; Woods, ME | 1 |
| An, X; Cao, Y; Chen, T; Deng, Y; Han, H; Shi, Y; Teng, X; Xue, C; Yang, W; Zhou, F | 1 |
| Habuchi, T; Horikawa, Y; Inoue, T; Kumazawa, T; Narita, S; Obara, T; Saito, M; Satoh, S; Tsuchiya, N; Yuasa, T | 1 |
| Barlow, LJ; Benson, MC; Desai, M; Laudano, MA; McKiernan, JM; Murphy, AM; Petrylak, DP | 1 |
| Konety, BR | 1 |
| Barlow, LJ; Benson, MC | 1 |
| Logothetis, C; Millikan, R | 1 |
| Chikazawa, M; Fukata, S; Inoue, K; Shuin, T; Yoshikawa, C | 1 |
| Dreicer, R; George, CS; Manola, J; Roth, BJ; Schneider, DJ; Schwerkoske, JF; Wilding, G | 1 |
| Allen, HJ; Baker, C; Bosserman, LD; Chapman, Y; Figlin, RA; Gitlitz, BJ; Patel, R; Sanchez, JD; Shapiro, RM | 1 |
| Arai, Y; Hoshi, S; Itoh, A; Ohyama, C; Okada, Y; Ono, K; Saito, S; Satoh, M; Sohma, F; Takeda, A; Yamashita, S; Yamato, T | 1 |
| Itoh, S; Mitsuhata, N; Watanabe, Y | 1 |
| Arai, Y; Habuchi, T; Horikawa, Y; Hoshi, S; Inoue, T; Kato, T; Matsuura, S; Ohyama, C; Saito, S; Sato, K; Satoh, S; Togashi, H; Tsuchiya, N | 1 |
| Alexopoulos, A; Ardavanis, A; Kandylis, C; Lainakis, G; Rigatos, G; Tryfonopoulos, D | 1 |
| Artz, A; Ryan, C; Stadler, WM; Vogelzang, NJ; Zimmerman, T | 1 |
| Fukata, S; Furihata, M; Inoue, K; Karashima, T; Kawada, C; Kurabayashi, A; Nomura, A; Ohtsuki, Y; Shuin, T | 1 |
| Ennist, DL; Ganesh, S; Ge, Y; Mina, M; Ramesh, N; Reddy, PS; Yu, DC; Zhu, M | 1 |
| Canil, C; Chi, KN; Moore, M; Murray, RN; Tinker, A; Winquist, E | 1 |
| Mackler, NJ; Pienta, KJ | 1 |
| Benson, MC; Desai, M; Goetzl, M; Masson, P; McKiernan, JM; Murphy, AM; Olsson, CA; Petrylak, DP | 1 |
| Adam, L; Brown, G; Dinney, CP; Kassouf, W; Luongo, T | 1 |
| Calabrò, F; Sternberg, CN | 1 |
| Aerts, R; De Boeck, G; De Bruijn, EA; Dumez, H; Guetens, G; Maes, RA; Martens, M; Selleslach, J; van Oosterom, AT | 1 |
| Engelmann, UH; Heidenreich, A; Ohlmann, CH; Ozgür, E; Pfister, D; Sahi, D; Thüer, D | 1 |
| Baldazzi, V; Carini, M; Crisci, A; Giordano, C; Grifoni, R; Lapini, A; Neri, B; Pantaleo, P; Raugei, A; Vannini, L | 1 |
| Faerber, GJ; Weizer, AZ; Wolf, JS | 1 |
| Bajorin, DF; Hilton, S; Kelly, WK; Mazumdar, M; McCaffrey, JA; Sadan, S; Scher, HI | 1 |
| Anagnostopoulos, A; Athanassiades, P; Deliveliotis, C; Dimopoulos, C; Dimopoulos, MA; Mitropoulos, D; Moulopoulos, LA; Papadimitriou, C | 1 |
| Antoine, EC; Khayat, D | 1 |
| Engelholm, SA; Kamby, C; Lund, B; Sengeløv, L | 1 |
| de Boer, M; de Wit, R; Kerger, J; Kruit, WH; Stoter, G; Verweij, J | 1 |
| Bateman, AC; Cook, T; Dunsford, ML; Mead, GM; Tung, K | 1 |
| Anagnostopoulos, A; Aravantinos, G; Bakoyannis, C; Bamias, A; Deliveliotis, C; Dimopoulos, MA; Fountzilas, G; Georgoulias, V; Giannopoulos, A; Karayannis, A; Kosmidis, P; Kyriakakis, Z; Moulopoulos, LA; Pantazopoulos, D; Papadimitriou, C; Varkarakis, I; Zervas, A | 1 |
| Akaza, H; Hattori, K | 1 |
| Aspropotamitis, A; Athanassiou, A; Dimitriadis, M; Halikia, A; Karvounis, N; Pectasides, D; Visvikis, A | 1 |
| Börgermann, C; Krege, S; Otto, T; Rembrink, V; Rübben, H | 1 |
| Malkowicz, SB; Vaughn, DJ | 1 |
| Athanassiou, A; Bountouroglou, N; Glotsos, J; Karvounis, N; Kouloubinis, A; Mitakidis, N; Pectasides, D; Ziras, N | 1 |
| Chen, Y; Dilley, J; Li, Y; Ramesh, N; Working, P; Yu, DC; Zhang, J | 1 |
11 review(s) available for docetaxel anhydrous and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
Local administration of large surface area microparticle docetaxel to solid carcinomas induces direct cytotoxicity and immune-mediated tumoricidal effects: preclinical and clinical studies.
Topics: Animals; Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Line, Tumor; Docetaxel; Humans; Mice; Tumor Microenvironment; Urinary Bladder Neoplasms | 2023 |
[50 years of systemic therapy of urinary bladder cancer].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Transitional Cell; Clinical Trials as Topic; CTLA-4 Antigen; Docetaxel; Humans; Immunotherapy; Neoplasm Metastasis; Programmed Cell Death 1 Receptor; Randomized Controlled Trials as Topic; Survival Rate; Urinary Bladder Neoplasms; Vinblastine | 2019 |
Docetaxel for the treatment of bladder cancer.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Docetaxel; Humans; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids; Urinary Bladder Neoplasms | 2015 |
Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Kidney Pelvis; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Taxoids; Ureteral Neoplasms | 2017 |
Experience with newer intravesical chemotherapy for high-risk non-muscle-invasive bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Humans; Mitomycin; Paclitaxel; Taxoids; Thiotepa; Treatment Failure; Urinary Bladder Neoplasms | 2013 |
Docetaxel in the management of advanced or metastatic urothelial tract cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Paclitaxel; Taxoids; Urologic Neoplasms | 2002 |
Drug insight: Use of docetaxel in prostate and urothelial cancers.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Transitional Cell; Clinical Trials as Topic; Docetaxel; Humans; Male; Prostatic Neoplasms; Taxoids; Urologic Neoplasms | 2005 |
State-of-the-art management of metastatic disease at initial presentation or recurrence.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Taxoids; Urinary Bladder Neoplasms | 2006 |
[The role of new drugs in the treatment of locally advanced urothelial tumors of the bladder].
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Paclitaxel; Taxoids; Urinary Bladder Neoplasms | 1998 |
[New combination chemotherapy in urological cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Humans; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Methotrexate; Paclitaxel; Prostatic Neoplasms; Taxoids; Testicular Neoplasms; Urinary Bladder Neoplasms; Vinblastine | 2000 |
Recent advances in bladder cancer chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Urinary Bladder Neoplasms | 2001 |
28 trial(s) available for docetaxel anhydrous and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Docetaxel; Humans; Platinum; Ramucirumab; Urinary Bladder Neoplasms | 2022 |
EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.
Topics: Antibodies, Monoclonal; Carcinoma, Transitional Cell; Docetaxel; Humans; Urinary Bladder Neoplasms | 2023 |
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Docetaxel; Humans; Immune Checkpoint Inhibitors; Receptors, Fibroblast Growth Factor; Urinary Bladder Neoplasms | 2023 |
Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Docetaxel; Female; Humans; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms; Vinblastine | 2020 |
Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Docetaxel; Double-Blind Method; Female; Humans; Male; Middle Aged; Neoplasm Staging; Quality of Life; Ramucirumab; Urologic Neoplasms | 2020 |
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Humans; Internationality; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Proportional Hazards Models; Ramucirumab; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms | 2017 |
Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2).
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Docetaxel; Down-Regulation; Drug Administration Schedule; Female; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Male; Middle Aged; Molecular Chaperones; Oligonucleotides; Recurrence; Survival Analysis; Treatment Outcome; Urologic Neoplasms | 2018 |
Pembrolizumab Combined With Either Docetaxel or Gemcitabine in Patients With Advanced or Metastatic Platinum-Refractory Urothelial Cancer: Results From a Phase I Study.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Feasibility Studies; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Platinum Compounds; Progression-Free Survival; Response Evaluation Criteria in Solid Tumors; Urologic Neoplasms | 2018 |
A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Salvage Therapy; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms | 2016 |
Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Docetaxel; Female; Humans; Male; Middle Aged; Ramucirumab; Taxoids; Urologic Neoplasms | 2016 |
Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Transitional Cell; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Humans; Male; Middle Aged; Taxoids; Time Factors; Treatment Failure; Urinary Bladder Neoplasms | 2010 |
Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Taxoids; Urologic Neoplasms; Urothelium | 2003 |
A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms | 2003 |
Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Taxoids; Treatment Outcome; Urologic Neoplasms; Urothelium | 2005 |
A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Male; Methotrexate; Middle Aged; Survival Analysis; Taxoids; Urinary Bladder Neoplasms; Urothelium | 2005 |
A phase I dose finding study of cisplatin, gemcitabine, and weekly docetaxel for patients with advanced transitional cell cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Taxoids; Urinary Bladder Neoplasms | 2006 |
Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Transitional Cell; Docetaxel; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Taxoids; Urinary Bladder Neoplasms | 2006 |
Docetaxel and gemcitabine combination therapy in advanced transitional cell carcinoma of the urothelium: results of a phase II and pharmacologic study.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cell Survival; Deoxycytidine; Docetaxel; Erythrocytes; Female; Gemcitabine; Humans; Male; Middle Aged; Taxoids; Urinary Bladder Neoplasms; Urothelium | 2007 |
Gemcitabine plus docetaxel as first-line biweekly therapy in locally advanced and/or metastatic urothelial carcinoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Outcome; Urologic Neoplasms; Urothelium | 2007 |
Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Transitional Cell; Docetaxel; Drug Hypersensitivity; Female; Humans; Male; Middle Aged; Paclitaxel; Remission Induction; Survival Analysis; Taxoids; Urologic Neoplasms | 1997 |
Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxel.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Transitional Cell; Docetaxel; Female; Humans; Kidney Diseases; Male; Middle Aged; Paclitaxel; Taxoids | 1998 |
Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Paclitaxel; Taxoids; Urologic Neoplasms | 1998 |
Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Transitional Cell; Disease Progression; Docetaxel; Drug Administration Schedule; Edema; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome; Urologic Neoplasms | 1998 |
Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Dyspnea; Fatal Outcome; Gemcitabine; Humans; Lung; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Severity of Illness Index; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms | 1999 |
Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter phase II study of the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Docetaxel; Female; Follow-Up Studies; Greece; Humans; Linear Models; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Remission Induction; Severity of Illness Index; Survival Rate; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms; Urothelium | 1999 |
Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Docetaxel; Epirubicin; Female; Humans; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Urinary Bladder Neoplasms | 2000 |
Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Disease-Free Survival; Docetaxel; Female; Humans; Ifosfamide; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Prospective Studies; Taxoids; Treatment Failure; Urologic Neoplasms | 2001 |
Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Taxoids; Urinary Bladder Neoplasms | 2002 |
24 other study(ies) available for docetaxel anhydrous and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
Chronological transition in outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval: a multicenter retrospective analysis.
Topics: Aged; Antibodies, Monoclonal, Humanized; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Retrospective Studies; Urinary Bladder Neoplasms | 2022 |
Sequential Chemotherapy with Gemcitabine and Docetaxel: Breaking the Chains of bacillus Calmette-Guérin.
Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Mycobacterium bovis; Urinary Bladder Neoplasms | 2022 |
Skeletal Muscle Mass Reduction Velocity as a Simple Prognostic Indicator for Patients with Metastatic Urothelial Carcinoma Receiving Second-Line Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Muscle, Skeletal; Prognosis; Retrospective Studies; Sarcopenia; Survival Rate; Urologic Neoplasms | 2019 |
Critical treatment choices for patients with platinum-refractory urothelial carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Carcinoma, Transitional Cell; Docetaxel; Double-Blind Method; Humans; Platinum; Ramucirumab; Urologic Neoplasms | 2020 |
Novel treatment of upper tract urothelial carcinoma in situ with docetaxel in BCG refractory patients.
Topics: Adjuvants, Immunologic; Aged; Aged, 80 and over; Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Cohort Studies; Docetaxel; Humans; Kidney Neoplasms; Middle Aged; Treatment Failure; Ureteral Neoplasms | 2021 |
Intravesicular taxane-induced dermatotoxicity in a 78-year-old man with urothelial carcinoma and primary cutaneous anaplastic large cell lymphoma.
Topics: Administration, Intravesical; Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Docetaxel; Drug Eruptions; Humans; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Male; Neoplasms, Multiple Primary; Taxoids; Urinary Bladder Neoplasms | 2018 |
Second-line systemic therapies for metastatic urothelial carcinoma: a population-based cohort analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Treatment Outcome; Urologic Neoplasms; Urothelium | 2019 |
Do patients with metastatic urothelial carcinoma benefit from docetaxel as second-line chemotherapy?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Transitional Cell; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Retrospective Studies; Salvage Therapy; Taxoids; Urinary Bladder Neoplasms | 2014 |
Regression of choroidal neovascularization in response to systemic chemotherapy for cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Choroidal Neovascularization; Cisplatin; Deoxycytidine; Docetaxel; Fatal Outcome; Fluorescein Angiography; Gemcitabine; Humans; Male; Remission Induction; Taxoids; Tomography, Optical Coherence; Urethral Neoplasms; Urinary Bladder Neoplasms | 2013 |
Sequential chemotherapy using gemcitabine + carboplatin followed by gemcitabine + carboplatin + docetaxel for advanced upper-tract urothelial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Creatinine; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome; Urologic Neoplasms | 2015 |
Ramucirumab plus docetaxel for urothelial carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Docetaxel; Humans; Ramucirumab; Taxoids; Urologic Neoplasms | 2016 |
Effectiveness of capecitabine with or without docetaxel therapy for the treatment of patients with advanced urothelial carcinoma: a single-institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Carcinoma, Transitional Cell; Disease-Free Survival; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Retrospective Studies; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2016 |
[Combination therapy consisting of gemcitabine, docetaxel and carboplatin as a second-line chemotherapy for patients with MVAC-treated metastatic urothelial carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Gemcitabine; Hematologic Diseases; Humans; Methotrexate; Neoplasm Metastasis; Retrospective Studies; Taxoids; Urologic Neoplasms; Vinblastine | 2008 |
Editorial comment.
Topics: Administration, Intravesical; Antineoplastic Agents; Carcinoma, Transitional Cell; Docetaxel; Humans; Taxoids; Urinary Bladder Neoplasms | 2010 |
Docetaxel enhances the therapeutic effect of the angiogenesis inhibitor TNP-470 (AGM-1470) in metastatic human transitional cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Carcinoma, Transitional Cell; Cyclohexanes; Docetaxel; Drug Synergism; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Paclitaxel; Sesquiterpenes; Taxoids; Time Factors; Transplantation, Heterologous; Urinary Bladder Neoplasms | 2003 |
Gemcitabine plus carboplatin; and gemcitabine, docetaxel, and carboplatin combined chemotherapy regimens in patients with metastatic urothelial carcinoma previously treated with a platinum-based regimen: preliminary report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pilot Projects; Taxoids; Treatment Outcome; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2004 |
[Multidisciplinary treatment for advanced bladder cancer--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Doxorubicin; Female; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Quality of Life; Taxoids; Urinary Bladder Neoplasms | 2004 |
[Active chemotherapy with gemcitabine, carboplatin and docetaxel for three patients with MVAC-resistant liver metastasis of urothelial carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Gemcitabine; Humans; Kidney Neoplasms; Liver Neoplasms; Male; Methotrexate; Middle Aged; Taxoids; Urinary Bladder Neoplasms; Vinblastine | 2004 |
Effect of combination therapy with a novel bisphosphonate, minodronate (YM529), and docetaxel on a model of bone metastasis by human transitional cell carcinoma.
Topics: Acid Phosphatase; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Bone Resorption; Carcinoma, Transitional Cell; Cell Line; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Docetaxel; Dose-Response Relationship, Drug; Humans; Imidazoles; Immunohistochemistry; In Situ Nick-End Labeling; Isoenzymes; Mice; Mice, Inbred BALB C; Mice, Nude; Osteoblasts; Proliferating Cell Nuclear Antigen; Tartrate-Resistant Acid Phosphatase; Taxoids; Tibia; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2005 |
CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer.
Topics: Adenoviridae; Adenovirus E1A Proteins; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Transitional Cell; Cell Line, Tumor; Docetaxel; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunohistochemistry; Mice; Mice, Nude; Oncolytic Virotherapy; Oncolytic Viruses; Retinoblastoma Protein; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2006 |
Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Transitional Cell; Docetaxel; Drug Administration Schedule; Gefitinib; Humans; Male; Mice; Mice, Inbred BALB C; Quinazolines; Taxoids; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2006 |
[Optimizing treatment of advanced urologic malignancies].
Topics: Carcinoma, Transitional Cell; Docetaxel; Drug Resistance, Neoplasm; Education, Medical, Graduate; Gene Expression Profiling; Humans; Lymphatic Metastasis; Male; Neoplasm Staging; Neoplasms, Germ Cell and Embryonal; Palliative Care; Prognosis; Prostatic Neoplasms; Quality Assurance, Health Care; Research; Taxoids; Testicular Neoplasms; Transurethral Resection of Prostate; Urinary Bladder Neoplasms; Urologic Neoplasms; Urology | 2007 |
Progression of disease despite good endoscopic local control of upper tract urothelial carcinoma.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease Progression; Docetaxel; Electrocoagulation; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Nephrectomy; Paclitaxel; Taxoids; Ureteroscopy | 2007 |
Identification of human uroplakin II promoter and its use in the construction of CG8840, a urothelium-specific adenovirus variant that eliminates established bladder tumors in combination with docetaxel.
Topics: Adenovirus E1B Proteins; Adenoviruses, Human; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Transitional Cell; Combined Modality Therapy; Cytopathogenic Effect, Viral; Docetaxel; Drug Synergism; Gene Deletion; Genes, Regulator; Humans; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Promoter Regions, Genetic; Taxoids; Urinary Bladder Neoplasms; Uroplakin II; Virus Replication; Xenograft Model Antitumor Assays | 2002 |